Drug Profile
1229U91
Alternative Names: GR 231118; GW 1229Latest Information Update: 08 Jun 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Banyu
- Class
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 14 Sep 2004 Discontinued - Preclinical for Obesity in Japan (unspecified route)
- 20 Feb 2001 Profile reviewed but no significant changes made
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline